Matches in Nanopublications for { ?s ?p "DDI between Paroxetine and Zuclopenthixol decanoate - Paroxetine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if paroxetine is initiated, discontinued or dose changed."@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00715_DB08920 title "DDI between Paroxetine and Zuclopenthixol decanoate - Paroxetine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if paroxetine is initiated, discontinued or dose changed." assertion.